Designer antiandrogens join the race against drug resistance

Abstract

By using in silico models of the complexes formed by analogues of a cancer drug and its receptor, it may be possible to strategically redesign existing drugs and win the race against mutations that lead to drug resistance in prostate cancer.

Keywords

• prostate cancer
• androgen receptor
• drug resistance